BIOCQ (Biocept) EBIT per Share: $-50.51 (TTM As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOCQ Biocept Inc BIOCQ
16 GF Score
Price $0.00
View Full Analysis

What is Biocept EBIT per Share?

Biocept BIOCQ -50.00% 16 EBIT per Share is $-50.51 as of Jun. 2023. GuruFocus rates BIOCQ with a GF Score™ of 16/100.

Biocept's EBIT per Share for the three months ended in Jun. 2023 was $-3.45. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-50.51.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Biocept's EBIT per Share or its related term are showing as below:

BIOCQ's 3-Year EBIT Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 13.2
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Biocept's EBIT for the three months ended in Jun. 2023 was $-3.58 Mil.

Biocept  (OTCPK:BIOCQ) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Biocept EBIT per Share Related Terms

Biocept EBIT per Share Historical Data

* Premium members only.

The historical data trend for Biocept's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocept EBIT per Share Chart

Biocept Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,695.44 -360.70 -44.48 -4.89 -56.45

Biocept Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.53 -17.77 -17.20 -12.09 -3.45
BIOCQ
16GF Score
Biocept Inc BIOCQ
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocept EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Biocept's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

EBIT per Share(A: Dec. 2022 )
=EBIT/Shares Outstanding (Diluted Average)
=-31.896/0.565
=-56.45

Biocept's EBIT per Share for the quarter that ended in Jun. 2023 is calculated as

EBIT per Share(Q: Jun. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-3.581/1.037
=-3.45

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-50.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-50.51 mean?
Biocept (BIOCQ) has a EBIT per Share of $-50.51 as of Jun. 2023. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Biocept and its competitors.
Is Biocept's EBIT per Share too high?
Biocept's current EBIT per Share is $-50.51. Overall, Biocept has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Biocept's EBIT per Share compare to IDTA and DIGP?
Biocept's EBIT per Share of $-50.51 can be compared against companies in the Medical Diagnostics & Research industry. The industry median EBIT per Share is 13.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.20, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Biocept and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocept's current EBIT per Share is $-50.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocept stock overvalued right now?
Biocept (BIOCQ) has a current EBIT per Share of $-50.51. The current EBIT per Share is $-50.51. Biocept's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Biocept (BIOCQ), the current EBIT per Share is $-50.51 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biocept Business Description

Address 9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
16GF Score

Get the complete analysis for BIOCQ

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price